Biosyntech Inc. Signs Agreement With MedQualis As BST-DermOn’TM’ And BST-InPod’TM’ Clinical Trial CRO

BIOSYNTECH (TSX Venture:BSY) is pleased to announce the appointment of MedQualis, a contract research organization (CRO) to support BioSyntech in their upcoming BST-DermOn(TM) and BST-InPod(TM) Canadian clinical trials.

MORE ON THIS TOPIC